Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Polyrizon Ltd. - Ordinary Shares
(NQ:
PLRZ
)
11.14
-0.17 (-1.50%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
32,956
Open
11.78
Bid (Size)
11.00 (2,000)
Ask (Size)
11.95 (100)
Prev. Close
11.31
Today's Range
10.71 - 12.20
52wk Range
0.0032 - 18.20
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
TechMediaBreaks – Polyrizon Ltd. (NASDAQ: PLRZ) Closes $3.5 Million Registered Direct Offering and Concurrent Private Placement
Today 10:48 EDT
Via
Investor Brand Network
Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement
April 07, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Performance
YTD
-12.6%
-12.6%
1 Month
-21.5%
-21.5%
3 Month
-19.5%
-19.5%
6 Month
+852.1%
+852.1%
1 Year
+2685.0%
+2685.0%
More News
Read More
Polyrizon Provides 2025 and Recent Highlights
March 26, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
March 25, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
PLRZ Stock Jumps 6% In Pre-Market – Why Is This Biotech Firm Diversifying Into Aviation Business?
↗
February 10, 2026
Via
Stocktwits
Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications
March 24, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program
March 17, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study
March 10, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
February 26, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator
February 10, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
February 06, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI
February 06, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company
February 04, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Top movers in Monday's session
↗
February 02, 2026
Via
Chartmill
Monday's session: top gainers and losers
↗
February 02, 2026
Via
Chartmill
Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker
January 22, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet
January 13, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™
January 08, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator
January 05, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Wondering what's happening in today's pre-market session?
↗
January 05, 2026
Via
Chartmill
Top stock movements in today's session.
↗
January 02, 2026
Via
Chartmill
As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated
January 02, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet
December 29, 2025
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses
December 19, 2025
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program
December 11, 2025
From
Polyrizon Ltd.
Via
GlobeNewswire
Frequently Asked Questions
Is Polyrizon Ltd. - Ordinary Shares publicly traded?
Yes, Polyrizon Ltd. - Ordinary Shares is publicly traded.
What exchange does Polyrizon Ltd. - Ordinary Shares trade on?
Polyrizon Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Polyrizon Ltd. - Ordinary Shares?
The ticker symbol for Polyrizon Ltd. - Ordinary Shares is PLRZ on the Nasdaq Stock Market
What is the current price of Polyrizon Ltd. - Ordinary Shares?
The current price of Polyrizon Ltd. - Ordinary Shares is 11.14
When was Polyrizon Ltd. - Ordinary Shares last traded?
The last trade of Polyrizon Ltd. - Ordinary Shares was at 04/15/26 04:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
